Provided by Tiger Fintech (Singapore) Pte. Ltd.

PDS Biotechnology Corporation

1.08
+0.04003.85%
Post-market: 1.080.00000.00%16:07 EDT
Volume:131.53K
Turnover:141.45K
Market Cap:49.03M
PE:-1.05
High:1.11
Open:1.05
Low:1.03
Close:1.04
Loading ...

PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Nov 2024

PDS Biotechnology (PDSB) Receives a Buy from Noble Financial

TIPRANKS
·
15 Nov 2024

PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

GuruFocus.com
·
15 Nov 2024

PDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

PDS Biotechnology Shares Down 18% After Phase 3 Trial Modifications

Dow Jones
·
15 Nov 2024

PDS Biotechnology: Q3 Earnings Snapshot

Associated Press Finance
·
14 Nov 2024

PDS Biotechnology Q3 2024 GAAP EPS $(0.29) Misses $(0.28) Estimate

Benzinga
·
14 Nov 2024

PDS Biotechnology Q3 Net Income USD -10.7 Million

THOMSON REUTERS
·
14 Nov 2024

PDS Biotechnology Q3 EPS USD -0.29 VS. Ibes Estimate USD -0.28

THOMSON REUTERS
·
14 Nov 2024

PDS Biotechnology Corp expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
12 Nov 2024

PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Oct 2024

PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know

Zacks
·
23 Oct 2024

BRIEF-Pds Biotech Announces Presentation Of Rationale And Design Of First Recurrent Prostate Cancer Trial To Combine An Androgen Receptor Pathway Inhibitor With An Immunocytokine

Reuters
·
22 Oct 2024

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor With an Immunocytokine

THOMSON REUTERS
·
22 Oct 2024